GALEAS Tumor (UKCA)

About Nonacus

Nonacus is a commercial-stage diagnostics company specializing in liquid biopsy NGS for precision medicine. Its core technology is the GALEAS platform, supported by the proprietary Cell3 Target enrichment system, which enables highly sensitive detection of genetic variants from minimal sample input. The company markets a portfolio of clinically validated panels for bladder cancer, solid tumors, and hereditary cancers, alongside custom panel design tools and sample collection/isolation kits. Positioned at the intersection of clinical diagnostics and research, Nonacus targets the growing demand for non-invasive genomic testing in oncology and genetic disease management.

Therapeutic Areas